Please enter the email address you used to register, then we will send you a link to choose a new password
Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage biopharmaceutical company committed to...
Craig-Hallum analyst Christian Schwab initiates coverage on Rezolute (NASDAQ:RZLT) with a Buy rating and announces Price Tar...
CRNX: 11% | Crinetics Pharmaceuticals shares are trading higher after the company announced the early release of ENDO 2024 late...
Rezolute announced topline results from the Phase 2 study of RZ402 for diabetic macular edema, showing significant improvements...
HC Wainwright & Co. analyst Douglas Tsao reiterates Rezolute (NASDAQ:RZLT) with a Buy and maintains $14 price target.